Arrowhead Research | ARWR - Operating Expenses


Arrowhead Research reported $245.35M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Moderna USD 1.18B 223M Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 9.88B 325M Sep/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
TG Therapeutics USD 174.04M 44.62M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026